HANGZHOU TIGERMED CO. H 1 (5HZ1) — Capital Reinvestment Ratio
HANGZHOU TIGERMED CO. H 1 (5HZ1) has a Capital Reinvestment Ratio of 0.19x as of December 2025, meaning it reinvests 0% of its operating cash flow (€1.12 Billion) in capital expenditures (€214.37 Million). Check 5HZ1 tangible net worth ratio to evaluate the tangible quality of the company's equity base.
Capital Reinvestment Ratio
Operating Cash Flow
Capital Expenditures
Data as of
HANGZHOU TIGERMED CO. H 1 Capital Reinvestment Ratio (2021–2025)
This chart tracks HANGZHOU TIGERMED CO. H 1's Capital Reinvestment Ratio across 5 annual periods. For the full cash flow conversion analysis, see HANGZHOU TIGERMED CO. H 1 (5HZ1) cash conversion ratio.
Annual Capital Reinvestment Ratio for HANGZHOU TIGERMED CO. H 1 (2021–2025)
Year-by-year Capital Reinvestment Ratio for HANGZHOU TIGERMED CO. H 1 from 2021 to 2025. See 5HZ1 free cash flow generation to measure how efficiently the company converts operating cash flow to free cash.
| Year | Reinvestment Ratio | Operating CF (EUR) | Capital Expenditures | YoY Change |
|---|---|---|---|---|
| 2025 | 0.19x | €1.12 Billion | €214.37 Million | ▼ -41.0% |
| 2024 | 0.33x | €1.10 Billion | €356.55 Million | ▲ +19.2% |
| 2023 | 0.27x | €1.15 Billion | €313.76 Million | ▼ -17.5% |
| 2022 | 0.33x | €1.36 Billion | €448.60 Million | ▲ +27.6% |
| 2021 | 0.26x | €1.42 Billion | €368.62 Million | — |